Gilead Sciences executive chairman transitions into chairman role

Gilead Sciences has announced that Dr John Martin will be transitioning from his current role of executive chairman to chairman of the board of directors, effective as of March 9th 2018.

Dr Martin was first named as executive chairman of the company in March 2016, after being succeeded as president and chief executive officer (CEO) by Dr John Milligan. He served as CEO of Gilead from 1996 to 2016, having joined the company in 1990.

During his time as CEO, Dr Martin was credited with building the company's portfolio to include 24 marketed products, with annual revenues of more than $32 billion (23.93 billion pounds).

Dr Milligan said: "John's scientific and business leadership has been notable for the development of Gilead's portfolio of HIV and viral hepatitis medicines and commitment to worldwide access for patients."

This comes after the firm promoted Dr Alessandro Riva to the role of executive vice-president for oncology therapeutics in October, handing him responsibility for Gilead's haematology and oncology programmes.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.